Takeda Pharmaceuticals and digital health tool developer Cognition Kit are collaborating on a study to assess whether mobile apps and wearables with continuous monitoring capabilities can be used to gather insights into depressive disorder.
Researchers will recruit 30 study participants aged 18 to 65 who have received a clinical diagnosis of mild to moderate depression and have been prescribed an antidepressant. Participants will be given an Apple Watch loaded with the cognitive assessment app designed by UK-based Cognition Kit.
The study aims to evaluate feasibility and compliance, and to understand how measures of mood and cognition on wearable technology compare to more traditional neuropsychological testing and patient reported assessments.
Read the press release